TIGIT-targeting therapies have largely disappointed in recent months, with failed studies, terminated partnerships and ...

New PICCOLO trial analyses showed that mirvetuximab soravtansine achieved 52% response rates and 27-month overall survival in ...

Brian Riley as President and Chief Technical Officer, Joanne Lager, MD as Chief Medical Officer, and Adrian Chaisson as Chief of Staff.

In collaboration with GSK, iTeos has decided to discontinue the belrestotug program after it failed to meet key clinical trial endpoints.

LONDON - GSK plc (LSE/NYSE:LON: GSK), in collaboration with iTeos Therapeutics, Inc., announced today the termination of their joint development program for belrestotug, an investigational anti-TIGIT ...

– GALAXIES Lung-201 did not meet established criteria for clinically meaningful improvements in progression free survival – Based on totality of data, iTeos and GSK have agreed to terminate ...

iTeos ends belrestotug program with GSK after Phase 2 trial fails to meet key survival goals; company explores strategic options to boost shareholder value.

Based on these results, iTeos and GSK have decided to terminate the belrestotug development program and end the collaboration. All belrestotug-containing cohorts are ending, and any new enrollment in ...

iTeos and GSK terminate belrestotug program after GALAXIES Lung-201 results fail to show significant progression-free survival improvements.

WATERTOWN, Mass. and GOSSELIES, Belgium - iTeos Therapeutics, Inc. (NASDAQ: ITOS), a biopharmaceutical company with a market capitalization of $265 million, and its partner GSK have decided to ...